- $5.10m
- -$4.98m
- $1.20m
Cellular therapy developer Longeveron's Q3 net loss widens
Brief: Longeveron Q3 EPS USD -0.39
Brief: Longeveron Entered Into Sales Agreement For Sale Of Shares - SEC Filing
Brief: Longeveron® Announces Key Leadership Updates
Brief: Longeveron® Announces U.S. FDA Approval Of Ind Application
Brief: Longeveron® Announces Completion Of Enrollment Of Pivotal Phase 2B Clinical Trial
Brief: Longeveron Says Board Confirms Cash-To-Equity Program Approval - SEC Filing
Brief: Longeveron Inc Files For Mixed Shelf Of Up To $70 Million - SEC Filing
Brief: Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B™) In Alzheimer’S Disease
Brief: Longeveron Says Elpis I Met Its Primary Endpoint Of Safety Through 1-Year Post-Treatment
Brief: Longeveron® Lomecel-B™ Data In Alzheimer’S Disease Selected For Late Breaking Poster Presentation At The Clinical Trials On Alzheimer’S Disease Conference
U.S. RESEARCH ROUNDUP- Antero Resources, Coterra Energy, Netflix
Brief: Longeveron Says Study Results From Clear Mind Phase 2A Clinical Trial Of Lomecel-B™ Achieved Primary Safety & Secondary Efficacy Endpoints
Longeveron soars on FDA's 'RMAT' tag for Alzheimer's therapy
U.S. STOCKS ON THE MOVE-Manchester United, Tesla, Illumina
Longeveron jumps on FDA's 'RMAT' tag for Alzheimer's therapy
Brief: Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation For The Treatment Of Mild Alzheimer’S Disease
Brief: Neha Motwani Elected to Longeveron® Board of Directors
Brief: Gene Therapy Pioneer Roger Hajjar, MD, Elected To Longeveron® Board Of Directors